The first two authors contributed equally to this work.
The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer
Article first published online: 15 APR 2014
© 2014 American Cancer Society
Volume 120, Issue 15, pages 2299–2307, August 1, 2014
How to Cite
Zhao, M., Zhang, Y., Cai, W., Li, J., Zhou, F., Cheng, N., Ren, R., Zhao, C., Li, X., Ren, S., Zhou, C. and Hirsch, F. R. (2014), The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer. Cancer, 120: 2299–2307. doi: 10.1002/cncr.28725
We thank Genosaber, Amoy Diagnostics Company, Ltd., and AstraZeneca for technical support.
- Issue published online: 21 JUL 2014
- Article first published online: 15 APR 2014
- Manuscript Revised: 20 FEB 2014
- Manuscript Accepted: 20 FEB 2014
- Manuscript Received: 15 NOV 2013
- tyrosine kinase inhibitors;
- non–small cell lung cancer;
- B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11;
- epidermal growth factor receptor;
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of patients with advanced non–small cell lung cancer (NSCLC) who have EGFR mutations. Recent studies have indicated that some patients with positive mutations were refractory to EGFR TKIs if they harbored a B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11 (Bim) deletion polymorphism. The objective of the current work was to retrospectively study the Bim deletion polymorphism in Chinese patients with NSCLC and its correlation with the efficacy of EGFR TKIs.
Distribution of the Bim polymorphism was detected using polymerase chain reaction analysis and direct sequencing of DNA from peripheral neutrophils in samples from 352 patients with NSCLC. Of the 352 patients, 166 who received TKI therapy and had an activating mutation identified were involved in further analysis. Progression-free survival (PFS) was the primary endpoint of the subsequent analyses, and the incidence of the Bim polymorphism and its relation to clinical benefit from EGFR TKIs also were investigated.
In total, 45 of 352 patient samples (12.8%) had the Bim deletion polymorphism, which was distributed randomly with regard to various clinical characteristics. In patients with EGFR mutations who received treatment with TKIs, the median PFS and the median objective response rate were 4.7 months and 25%, respectively, for those with the Bim deletion polymorphism versus 11 months (P = .003) and 66% (P = .001), respectively, for those with wild-type Bim. Cox regression analysis identified Bim status (P = .016) and sex (P = .002) as independent factors predicting clinical benefit from EGFR TKIs in patients with EGFR-mutated NSCLC.
The incidence of the Bim deletion polymorphism was approximately 13% in this study, and it was associated with a poor clinical response to EGFR TKIs in patients who had NSCLC with EGFR mutations. Cancer 2014;120:2299–2307. © 2014 American Cancer Society.